The strong Phase 2 data supports SPY001 as a best-in-class anti-α4β7 candidate, with potential for accelerated development. Traders should monitor upcoming data readouts for SPY002 (mid-2026) and SPY003 (Q3 2026), as well as enrollment trends in combination arms, which could further de-risk the pipeline and attract partnership interest.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $63.27entry
- T+1 · 7mo ago +1.17%α −0.04% · $64.01
- T+5 · 7mo ago +15.99%α +12.70% · $73.39
- T+20 · 6mo ago +20.80%α +13.07% · $76.43
- T+60 · 4mo ago +50.78%α +41.86% · $95.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial, showing SPY001 achieved a statistically significant 9.2-point reduction in RHI score (p<0.0001) with strong secondary outcomes and a favorable safety profile. Enrollment has closed for Part A and moved to Part B, which includes monotherapy and combination cohorts, with data readouts expected through 2026–2027.
Key Facts
- SPY001 met primary endpoint with 9.2-point reduction in RHI score (p<0.0001) at Week 12 in Phase 2 SKYLINE trial Part A.
- Secondary endpoints: 40% clinical remission rate and 51% endoscopic improvement rate.
- SPY001 was well tolerated with no drug-related serious adverse events; most common AE was back pain (n=2).
- Part B of the SKYLINE trial is now enrolling, including combination cohorts with SPY002 and SPY003.
- Proof-of-concept data for SPY002 expected mid-2026, SPY003 in Q3 2026, and full Part B data in 2027.
Financial Impact
Potential blockbuster profile for SPY001 in ulcerative colitis, with best-in-class positioning and combination potential driving valuation upside.
Risk Factors
- Future data may not confirm current results, especially in randomized, placebo-controlled Part B.
- Regulatory disagreement with trial design or endpoints could delay approval path.
- Competition from existing anti-integrin and anti-cytokine therapies in IBD space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272353 |
Track record
36 reports on SYRE
7 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers